Skip to main content


Identification of Rare Autoimmune Events Following Administration of Immunotherapy Drugs (irAE-ID) is part of The National Patient-Centered Clinical Research Network (PCORnet)’s Cancer Collaborative Research Group’s initiative to stimulate collaborative projects that use PCORnet resources. Working with two PCORnet networks, the Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN) and the Stakeholder, Technology and Research (STAR) Network, the project has two primary aims:

  1. To test the feasibility of developing computational phenotyping algorithms to identify patients with checkpoint inhibitor-sensitive cancers who are treated with immunotherapeutic regimens;
  2. To assess the rate of occurrence for a rare immunotoxic autoimmune event (Type 1 Diabetes) with long term consequences for patient health.

The computational phenotypes developed in this project could significantly accelerate the identification of rare but significant immune-related adverse events (irAE). The project could be a platform for future identification of biomarkers of irAE to support precision medicine approaches for employing immunotherapy that minimize the potential for irreversible autoimmune damage.

Principal Investigator:
Theresa Walunas, PhD

CHIP Collaborators:
Al’ona Furmanchuck, PhD

Funding for this project is provided by Patient-Centered Outcomes Research Institute (PCORI). Grant Number: CDRN-1306-04737.

Jeffrey Sosman, MD, Northwestern Medicine, Department of Hematology and Oncology
Christine Micheel, PhD, Vanderbilt University
Zoe Quandt, MD, University of California San Francisco
Carlos Galvez, MD, Northwestern Medicine, Department of Hematology and Oncology
Saya Jacob, MD, Northwestern Medicine

Follow CHIP on LinkedIn